SKIN CARE
highly targeted enzymes without genetic modification. This technology can greatly improve the production process by utilizing the culture solution itself or its solid content as a biocatalyst for reactions without isolating and purifying the enzyme.2 The production uses plant-derived
materials, soybeans, that also are not genetically modified. Both the bacteria and soybeans are non-GMO. Furthermore, our whole-cell enzyme technology upcycles lecithin derived from the by-products of soybean oil production and turns it into a high percentage of bioactive lysophosphatidic acid (Figure 1).
Giving keratinocytes the ability to produce a healthy skin barrier The main purpose of the skin barrier is for protection and moisture retention. The skin barrier serves to keep foreign materials out and to keep moisture inside. When the barrier function becomes weak, the skin will allow entry of foreign materials, resulting to irritation. A skin barrier dysfunction often surfaces
in the form of problems such as sensitive skin and dry skin. There are several ways to produce healthy skin barrier, and one is to supply components to the skin that will hold onto water. Filaggrin, which degrades into amino acids (NMF) in the stratum corneum (SC), retains moisture and thus passively increases skin moisture.3 The other way to hydrate the skin is by
creating a barrier, to prevent the moisture from going out of the skin. It involves the ceramides, which make up almost 55% of intercellular lipids that hold the corneocytes together at the stratum corneum. To investigate the effects of the lysolecithin
ingredient on SC components, a full 3D skin model was used. Pro-filaggrin, which was detected using dot blot, was increased 4.8 times after one week of treatment of lysolecithin ingredient in comparison to the control (Figure 2A). Another SC component, which correlates
well with skin moisture and TEWL, are ceramides. After treatment of a 3D skin model with lysolecithin ingredient, total ceramides
TABLE 1: 0.1% LYSOLECITHIN FORMULATION INCI
Behenyl Alcohol, Polyglyceryl-10 Pentastearate, Sodium Stearoyl Lactylate
Hydrogenated Lecithin Squalane
Triethylhexanoin
Simmondsia Chinensis (Jojoba) Seed Oil Macadamia Ternifolia Seed Oil Cyclopentasiloxane Tocopherol
Phenoxyethanol Butylene Glycol Pentylene Glycol
Xanthan Gum, Water (2% aq.) Carbomer, Water (2% aq.)
Potassium Hydroxide, Water (1% aq.) Lysolecithin Water
www.personalcaremagazine.com
Figure 2: The factors related to the barrier function of keratinocytes supported by lysolecithin ingredient are shown in the hexagonal image. A: Barrier-related protein; B: Barrier-related lipid; C: Tight junction images; D scratch assay images. The bar graph of (A) shows the immunoblot intensity index of filaggrin detected from reconstructed 3D skin treated with 0.01% lysolecithin ingredient for seven days. The bar graph of (B) shows the index of ceramide detected from reconstructed 3D skin treated with 0.1% lysolecithin ingredient for 24 hours. Representative immunofluorescence images show the occludin detected from NHEKs treated with 10 µg/mL lysolecithin ingredient for 48 hours. Scale bar: 200 µm. Representative scratch assay images shows cell proliferation/migration detected from NHEKs treated with 10 µg/mL lysolecithin ingredient for 24 hours. Initial scratch distance: 0.62 mm. Statistical significance was determined by student’s t-test, (n=3)
(detected by LC-MS), significantly increased by 1.4 times compared to the control (Figure 2A). Occludins are part of your tight junction barrier; they form an impenetrable wall located between the cells so that no water or foreign materials can pass (Figure 2C). In addition, cell proliferation, cell migration,
and resistance to stress are also important factors. It is reported that lysophosphatidic acid promotes wound healing. A good method to study wound healing is to analyze the migration of confluent cells in a scratch assay.
0.1% Lysolecithin milk 1.20
0.50 3.00 5.00 1.00 1.00 1.00 0.10 0.40 3.00 4.00 5.00 4.00 3.00 0.10
67.70
Placebo milk 1.20
0.50 3.00 5.00 1.00 1.00 1.00 0.10 0.40 3.00 4.00 5.00 4.00 3.00 -
67.80
A silicon chamber was used to create artificial scratches that are uniform in size. In this experiment, each scratch was made by the removal of the silicon sheet, and afterwards the cells were treated with the lysolecithin ingredient for 24 hours on one of the scratches and left untreated on the control. The cells of both samples were then treated
with calcein in order to visualize the results in a fluorescent microscope. In the resulting figure, the thick black area is the scratch, and the blue area is the keratinocytes. The results have shown that the lysolecithin ingredient-treated scratch has better closing capability compared to the control. The cells in the leading edge of the scratch,
presented by arrows, have migrated towards the centre. In the lysolecithin ingredient-treated scratch, there are more cells migrating towards the centre. In a wound, this is important because the
faster the cells can get to the wound site, the faster it will heal. Therefore, the lysolecithin ingredient was found to promote migration of the cells in a scratch assay (Figure 2D).
Resolves sensitive skin symptoms A clinical study was conducted to investigate the changes in skin physiological indicators before and after continuous use of lysolecithin ingredient in subjects with sensitive skin (LAST positive subjects). The formulation used is in a form of milky emulsion. The composition of the formulation is shown in Table 1. The clinical study was done on 13
April 2024 PERSONAL CARE
61
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154
